Zydus receives approval from the USFDA to initiate Phase 2 clinical trials of Saroglitazar in patients with Non-Alcoholic Steatohepatitis (NASH) of the liver in USA. - 04/06/2016
Zydus receives approval from the USFDA to initiate Phase 2 clinical trials of Saroglitazar in patients with Non-Alcoholic Steatohepatitis (NASH) of the liver in USA. - 04/06/2016 — ZYDUS LIFESCIENCES LIMITED
